Mereo BioPharma (MREO) Operating Margin (2023 - 2025)

Mereo BioPharma (MREO) posted quarterly Operating Margin of 2099.8% for Q2 2025, down 194.58% on a QoQ basis from 712.8% in Q4 2023.

Mereo BioPharma (MREO) Operating Margin (2023 - 2025) Analysis & Trends

Mereo BioPharma (MREO) has reported Operating Margin for 2 consecutive years, with 2099.8% the latest figure, recorded in Q2 2025.

Quarterly Operating Margin changed N/A year-over-year to 2099.8% in Q2 2025, while the trailing twelve-month figure through Dec 2025 was 8021.2% (changed N/A YoY) and the FY2025 annual result came in at 8021.4%, changed N/A from the prior year.
Operating Margin fell to 2099.8% in Q2 2025 per MREO's latest filing, from 712.8% in the prior quarter.
Over the last five years, Operating Margin for MREO reached as high as 9.01% in Q2 2023 and fell as low as 2099.8% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Mereo BioPharma	232.52 Mn	232.52 Mn	-	-

Download Data